Butazocare Flavour 1g Granules in Sachet for Horses and Ponies

দেশ: যুক্তরাজ্য

ভাষা: ইংরেজি

সূত্র: VMD (Veterinary Medicines Directorate)

সক্রিয় উপাদান:

Phenylbutazone

থেকে পাওয়া:

Ecuphar NV

এটিসি কোড:

QM01AA01

INN (আন্তর্জাতিক নাম):

Phenylbutazone

ফার্মাসিউটিকাল ফর্ম:

Oral powder

প্রেসক্রিপশন টাইপ:

POM-V - Prescription Only Medicine – Veterinarian

থেরাপিউটিক গ্রুপ:

Horses

থেরাপিউটিক এলাকা:

Anti Inflammatory NSAID

অনুমোদন অবস্থা:

Authorized

অনুমোদন তারিখ:

2019-04-16

পণ্য বৈশিষ্ট্য

Revised: August 2022
AN: 01024/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Butazocare flavour 1g granules in sachet for horses and ponies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE: per sachet
Phenylbutazone (microencapsulated)
1g
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
White to off-white granules in sachet for oral administration.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and ponies (non-food producing).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of musculoskeletal disorders in horses and ponies
where the anti-
inflammatory and analgesic properties of phenylbutazone can offer
relief. Examples
of conditions normally considered suitable for treatment with
phenylbutazone include
lameness
associated
with
osteoarthritic
conditions,
acute
and
chronic
laminitis,
bursitis and carpitis, and in the reduction of post-surgical soft
tissue reaction.
4.3
CONTRAINDICATIONS
Do not use in animals suffering from cardiac, hepatic or renal
disease; where there is
the possibility of gastrointestinal ulceration or bleeding; or where
there is evidence of
a blood dyscrasia.
Do not use in animals suffering from gastrointestinal diseases.
Do not use in animals with haemorrhagic diathesis.
Do not use in cases of known hypersensitivity to the active substance
or to any of the
excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The clinical effect of phenylbutazone can be evident for at least
three days following
cessation of administration. This should be borne in mind when
examining horses for
soundness.
Revised: August 2022
AN: 01024/2022
Page 2 of 5
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Use in any animal under six weeks of age, or in aged animals, may
involve additional
risks. If such use cannot be avoided, animals may require a reduced
dosage and
special clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as
there is a risk
of